EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Chidamide plus envafolimab as subsequent treatment in advanced non‐small cell lung cancer patients resistant to anti‐PD‐1 therapy: A multicohort, open‐label, phase II trial with biomarker analysis

Yaxiong Zhang, Zihong Chen iD, Yu Liu, Liang Han, Wei Jiang, Qiming Wang, Jianhua Shi, Liqin Lu, Jianying Li, Mingjun Zhang, Yan Huang, Yunpeng Yang und 5 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.7175 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2024. Verfasst von Yaxiong Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborat…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents, Immunological, Aminopyridines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangzhou Municipal Science and Technology Program key projects, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Combination of chidamide and anti‐PD‐L1 inhibitor produce synergistic anti‐tumor effect in advanced NSCLC patients resistant to anti‐PD‐1 treatment. However, the effect of chidamide plus envafolimab has not been reported.

Aims

This study aimed to evaluate the efficacy of chidamide plus envafolimab in advanced NSCLC patients resistant toanti‐PD‐1 treatment. Materials and Methods Eligible advanced NSCLC patients after resistant to anti‐PD‐1 therapy received chidamide and envafolimab. The primary endpoint was objective response rate (ORR). The secondary end points included disease control rate (DCR), progression‐free survival (PFS), and safety. The expression of histone deacetylase 2 (HDAC2), PD‐L1, and blood TMB (bTMB) was also analyzed.

Results

After a median follow‐up of 8.1 (range: 7.6–9.2) months, only two patients achieved partial response. The ORR was 6.7% (2/30), DCR was 50% (15/30), and median PFS (mPFS) was 3.5 (95% confidence interval: 1.9–5.5) months. Biomarker analysis revealed that patients with high‐level HDAC2 expression had numerically superior ORR (4.3% vs. 0), DCR (52.2% vs. 0) and mPFS (3.7 vs. 1.4m). Patients with negative PD‐L1 had numerically superior DCR (52.2% vs. 33.3%) and mPFS (3.7m vs. 1.8m), so were those with low‐level bTMB (DCR: 59.1% vs. 16.7%, mPFS: 3.8 vs.1.9m). Overall safety was controllable.

Discussion

High HDAC2patients showed better ORR, DCR, and PFS. In addition, patient with negative PD‐L1 and low‐level bTMB had better DCR and PFS. This may be related to the epigenetic function of chidamide. However, the sample size was not big enough, so it is necessary to increase sample size to confirm the conclusion.

Conclusion

Combination of chidamide and envafolimab showed efficacy signals in certain NSCLC patients. But further identification of beneficial population is necessary for precision treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntineoplastic Agents, ImmunologicalAminopyridinesBenzamidesAntibodies, Monoclonal, HumanizedHumansB7-H1 AntigenBiomarkers

Stichwörter der Autor:innen

PD‐1/PD‐L1chidamideenvafolimabnon‐small cell lung cancerresistant

Substanzen

envafolimabB7-H1 AntigenN-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamideAntineoplastic Agents, ImmunologicalBiomarkersAminopyridinesBenzamidesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Canc…
  • Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
  • Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Can…
  • Department of Oncology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
  • Department of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
  • Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China.

ORCID-Profile: Zihong Chen, Xue Hou, Li Zhang, Jing Li, Gang Chen

Förderung

  • National Natural Science Foundation of China
  • Guangzhou Municipal Science and Technology Program key projects
  • Guangdong Basic and Applied Basic Research Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Zhang, Y., Chen, Z., Liu, Y., Han, L., Jiang, W., Wang, Q., Shi, J., Lu, L., Li, J., Zhang, M., Huang, Y., Yang, Y., Hou, X., Zhang, L., Li, J., Fang, W., & Chen, G. (2024). Chidamide plus envafolimab as subsequent treatment in advanced non‐small cell lung cancer patients resistant to anti‐PD‐1 therapy: A multicohort, open‐label, phase II trial with biomarker analysis. Cancer Medicine. https://doi.org/10.1002/cam4.7175

Vancouver

Zhang Y, Chen Z, Liu Y, Han L, Jiang W, Wang Q, et al. Chidamide plus envafolimab as subsequent treatment in advanced non‐small cell lung cancer patients resistant to anti‐PD‐1 therapy: A multicohort, open‐label, phase II trial with biomarker analysis. Cancer Medicine. 2024. doi:10.1002/cam4.7175

BibTeX
@article{Zhang2024,
  author = {Zhang, Yaxiong and Chen, Zihong and Liu, Yu and Han, Liang and Jiang, Wei and Wang, Qiming and Shi, Jianhua and Lu, Liqin and Li, Jianying and Zhang, Mingjun and Huang, Yan and Yang, Yunpeng and Hou, Xue and Zhang, Li and Li, Jing and Fang, Wenfeng and Chen, Gang},
  title = {Chidamide plus envafolimab as subsequent treatment in advanced non‐small cell lung cancer patients resistant to anti‐PD‐1 therapy: A multicohort, open‐label, phase II trial with biomarker analysis},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7175}
}
Kostenlos starten →